Safety Study of AMG 228 to Treat Solid Tumors

NCT02437916 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancy
Advanced Solid Tumors
Cancer
Oncology
Oncology Patients
Tumors
Melanoma
Non-small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck
Transitional Cell Carinoma of Bladder
Colorectal Cancer

Interventions

DRUG: AMG 228

Sponsor

Amgen